LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of SteadyMed Ltd. (“SteadyMed” or the “Company”) (Nasdaq: STDY).
If you purchased or otherwise acquired SteadyMed shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether SteadyMed and certain of its officers and/or directors violated federal securities laws. On August 31, 2017, the Company announced that it received a Refusal to File letter from the U.S. Food and & Drug Administration (the “FDA”) concerning its New Drug Application (“NDA”) for Treyvent, a pulmonary arterial hypertension treatment. Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. Following this news, SteadyMed’s stock price dropped.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.